Acute neuronal injury, excitotoxicity, and the endocannabinoid system

Molecular Neurobiology

Volumn 26, Issue 2-3, 2002, Pages 317-346

  van der Stelt, Mario ^a   Veldhuis, Wouter B ^b,c   Maccarrone, Mauro ^d   Bär, Peter R ^c   Nicolay, Klaas ^b   Veldink, Gerrit A ^a   Di Marzo, Vincenzo ^e   Vliegenthart, Johannes F G ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e CNR   (Italy)

Author keywords

2 arachidonoylglycerol; Anandamide; Cannabinoid; Excitotoxicity; Neurodegeneration; Neuroprotection

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CALCIUM; CANNABINOID; CANNABINOID RECEPTOR; NOLADIN ETHER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN INJURY; CALCIUM TRANSPORT; CELL DAMAGE; DISEASE TRANSMISSION; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; GABAERGIC TRANSMISSION; NERVE CELL LESION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION;

EID: 0036773310     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:26:2-3:317     Document Type: Article

References (176)

1. Di Marzo, V. (1998) 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: Biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta. 1392, 153-175.
2. Hanus, L., Gopher, A., Almog, S, and Mechoulam, R. (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36, 3032-3034.
3. Devane, W. A., Hanus, L., Breuer, A., et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
4. Mechoulam, R., Ben-Shabat, S., Hanus, L., et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
5. Sugiura, T., Kondo, S., Sukagawa, A., et al. (1995) 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97.
6. Hanus, L., Abu-Lafi, S., Fride, E., et al. (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98, 3662-3665.
7. Lambert, D. M. and Di Marzo, V. (1999) The palmitoylethanolamide and oleamide enigmas: Are these two fatty acid amides cannabimimetic? Curr. Med. Chem. 6, 757-737.
8. Lambert, D. M., Vandevoorde, S., Jonsson, K. O., and Fowler, C. J. (2002) The palmitoylethanolamide family: A new class of anti-inflammatory agents? Curr. Med. Chem. 9, 663-676.
9. Di Marzo, V., Melck, D., Bisogno, T., and De Petrocellis, L. (1998) Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521-528.
10. Hansen, H. S., Moesgaard, B., Hansen, H. H., and Petersen, G. (2000) N-Acylethanolamines and precursor phospholipids - Relation to cell injury. Chem. Phys. Lipids 108, 135-150.
11. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C., and Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
12. Hansen, H. S., Moesgaard, B., Hansen, H. H., Schousboe, A., and Petersen, G. (1999) Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Lipids 34, S327-S330.
13. Ueda, N., Liu, Q., and Yamanaka, K. (2001) Marked activation of the N-acylphosphatidylethanolamine-hydrolyzing phosphodiesterase by divalent cations. Biochim. Biophys. Acta. 1532, 121-127.
14. Schmid, H. H. (2000) Pathways and mechanisms of N-acylethanolamine biosynthesis: Can anandamide be generated selectively? Chem. Phys. Lipids 108, 71-87.
15. Di Marzo, V., De Petrocellis, L., Sugiura, T., and Waku, K. (1996) Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoylglycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227, 281-288.
16. Stella, N., Schweitzer, P., and Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
17. Bisogno, T., Melck, D., De Petrocellis, L., and Di Marzo, V. (1999) Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72, 2113-2119.
18. Pertwee, R. G. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129-180.
19. Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D., and Hipkin, R. W. (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. Mol. Pharmacol. 57, 1045-1050.
20. Herkenham, M., Lynn, A. B., Johnson, M. R., Melvin, L. S., de Costa, B. R., and Rice, K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 11, 563-583.
21. Grundy, R. I., Rabuffetti, M., and Beltramo, M. (2001) Cannabinoids and neuroprotection. Mol. Neurobiol. 24, 29-51.
22. Sagan, S., Venance, L., Torrens, Y., Cordier, J., Glowinski, J., and Giaume, C. (1999) Anandamide and WIN55212-2 inhibit cyclic AMP formation through G- protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. J. Neurosci. 11, 691-699.
23. Venance, L., Piomelli, D., Glowinski, J., and Giaume, C. (1995) Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376, 590-594.
24. Di Marzo, V., Breivogel, C. S., Tao, Q., et al. (2000) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75, 2434-2444.
25. Breivogel, C. S., Griffin, G., Di Marzo, V., and Martin, B. R. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60, 155-163.
26. Jarai, Z., Wagner, J. A., Varga, K., et al. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA 96, 14,136-14,141.
27. Howlett, A. C. and Mukhopadhyay, S. (2000) Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids 108, 53-70.
28. Maingret, F., Patel, A. J., Lazdunski, M., and Honore, E. (2001) The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J. 20, 47-54.
29. Chemin, J., Monteil, A., Perez-Reyes, E., Nargeot, J., and Lory, P. (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20, 7033-7040.
30. Zygmunt, P. M., Petersson, J., Andersson, D. A., et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457.
31. Smart, D. and Jerman, J. C. (2000) Anandamide: An endogenous activator of the vanilloid receptor. Trends Pharmacol. Sci. 21, 134.
32. Di Marzo, V., Bisogno, T., and De Petrocellis, L. (2001) Anandamide: Some like it hot. Trends Pharmacol. Sci. 22, 346-349.
33. De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agro, A., and Di Marzo, V. (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276, 12,856-12,863.
34. Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D., and De Petrocellis, L. (1998) The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: Connections with anandamide. Biochem. J. 331, 15-19.
35. Bisogno, T., MacCarrone, M., De Petrocellis, L., et al. (2001) The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur. J. Biochem. 268, 1982-1989.
36. Jarrahian, A., Manna, S., Edgemond, W. S., Campbell, W. B., and Hillard, C. J. (2000) Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J. Neurochem. 74, 2597-2606.
37. Fezza, F., Bisogno, T., Minassi, A., Appendino, G., Mechoulam, R., and Di Marzo, V. (2002) Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513, 294-298.
38. Hillard, C. J., Edgemond, W. S., Jarrahian, A., and Campbell, W. B. (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via faciliated diffusion. J. Neurochem. 69, 631-638.
39. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87.
40. Ueda, N. and Yamamoto, S. (2000) Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat. 61, 19-28.
41. Cravatt, B. F., Demarest, K., Patricelli, M. P., et al. (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA 98, 9371-9376.
42. Di Marzo, V., Bisogno, T., De Petrocellis, L., et al. (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264, 258-267.
43. Goparaju, S. K., Ueda, N., Taniguchi, K., and Yamamoto, S. (1999) Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol. 57, 417-423.
44. Ueda, N., Yamanaka, K., and Yamamoto, S. (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 276, 35,552-35,527.
45. Burstein, S. H., Rossetti, R. G., Yagen, B., and Zurier, R. B. (2000) Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat. 61, 29-41.
46. Maccarrone, M., De Petrocellis, L., Bari, M., Fezza, F., Salvati, S., Di Marzo, V., and Finazzi-Agro, A. (2001) Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch. Biochem. Biophys. 393, 321-328.
47. Maccarrone, M., Fiorucci, L., Erba, F., Bari, M., Finazzi-Agro, A., and Ascoli, F. (2000) Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett. 468, 176-180.
48. Mechoulam, R., Fride, E., Hanus, L., Sheskin, T., Bisogno, T., Di Marzo, V., Bayewitch, M., and Vogel, Z. (1997) Anandamide may mediate sleep induction. Nature 389, 25-26.
49. Ben-Shabat, S., Fride, E., Sheskin, T., et al. (1998) An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23-31.
50. Maurelli, S., Bisogno, T., De Petrocellis, L., Di Luccia, A., Marino, G., and Di Marzo, V. (1995) Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett. 377, 82-86.
51. Maccarrone, M., van der Stelt, M., Rossi, A., Veldink, G. A., Vliegenthart, J. F., and Agro, A. F. (1998) Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273, 32,332-32,339.
52. Maccarrone, M., Bari, M., Lorenzon, T., Bisogno, T., Di Marzo, V., and Finazzi-Agro, A. (2000) Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J. Biol. Chem. 275, 13,484-13,492.
53. Deadwyler, S. A., Hampson, R. E., Mu, J., Whyte, A., and Childers, S. (1995) Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273, 734-743.
54. Deadwyler, S. A., Hampson, R. E., Bennett, B. A., et al. (1993) Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels 1, 121-134.
55. Glass, M. and Felder, C. C. (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17, 5327-5333.
56. Sugiura, T., Kodaka, T., Nakane, S., et al. (1999) Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, either-linked analogues, and related compounds. J. Biol. Chem. 274, 2794-2801.
57. Sugiura, T., Kondo, S., Kishimoto, S., et al. (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275, 605-612.
58. Felder, C. C., Briley, E. M., Axelrod, J., Simpson, J. T., Mackie, K., and Devane, W. A. (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA 90, 7656-7660.
59. Felder, C. C., Joyce, K. E., Briley, E. M., et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48, 443-450.
60. Hampson, A. J., Bornheim, L. M., Scanziani, M., et al. (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70, 671-676.
61. Akinshola, B. E., Taylor, R. E., Ogunseitan, A. B., and Onaivi, E. S. (1999) Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Naunyn. Schmiedebergs Arch. Pharmacol. 360, 242-248.
62. Netzeband, J. G., Conroy, S. M., Parsons, K. L., and Gruol, D. L. (1999) Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture. J. Neurosci. 19, 8765-8777.
63. Schlicker, E. and Kathmann, M. (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565-572.
64. Logan, W. J. and Snyder, S. H. (1971) Unique high affinity uptake systems for glycine, glutamic and aspartic acids in central nervous tissue of the rat. Nature 234, 297-299.
65. Shen, M., Piser, T. M., Seybold, V. S., and Thayer, S. A. (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16, 4322-4334.
66. Al-Hayani, A. and Davies, S. N. (2000) Cannabinoid receptor mediated inhibition of excitatory synaptic transmission in the rat hippocampal slice is developmentally regulated. Br. J. Pharmacol. 131, 663-665.
67. Terranova, J. P., Michaud, J. C., Le Fur, G., and Soubrie, P. (1995) Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: Reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn. Schmiedebergs Arch. Pharmacol. 352, 576-579.
68. Hajos, N., Ledent, C., and Freund, T. F. (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106, 1-4.
69. Huang, C. C., Lo, S. W., and Hsu, K. S. (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 532, 731-748.
70. Gerdeman, G. and Lovinger, D. M. (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J. Neurophysiol. 85, 468-471.
71. Levenes, C., Daniel, H., Soubrie, P., and Crepel, E (1998) Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J. Physiol. 510, 867-879.
72. Szabo, B., Wallmichrath, I., Mathonia, P., and Pfreundtner, C. (2000) Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97, 89-97.
73. Morisset, V. and Urban, L. (2001) Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J. Neurophysiol. 86, 40-48.
74. Robbe, D., Alonso, G., Duchamp, F., Bockaert, J., and Manzoni, O. J. (2001) Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J. Neurosci. 21, 109-116.
75. Vaughan, C. W., Connor, M., Bagley, E. E., and Christie, M. J. (2000) Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol. 57, 288-295.
76. Auclair, N., Otani, S., Soubrie, P., and Crepel, F. (2000) Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol. 83, 3287-3293.
77. Ferraro, L., Tomasini, M. C., Gessa, G. L., Bebe, B. W., Tanganelli, S., and Antonelli, T. (2001) The cannabinoid receptor agonist WIN55,212-2 regulates glutamate transmission in rat cerebral cortex: An in vivo and in vitro study. Cereb. Cortex 11, 728-733.
78. Wilson, R. I., Kunos, G., and Nicoll, R. A. (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31, 453-462.
79. Wilson, R. I. and Nicoll, R. A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592.
80. Maejima, T., Hashimoto, K., Yoshida, T., Aiba, A., and Kano, M. (2001) Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31, 463-475.
81. Maejima, T., Ohno-Shosaku, T., and Kano, M. (2001) Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neurosci. Res. 40, 205-210.
82. Kreitzer, A. C. and Regehr, W. G. (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29, 717-727.
83. Kreitzer, A. C. and Regehr, W. G. (2001) Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J. Neurosci. 21, RC174.
84. Ohno-Shosaku, T., Maejima, T., and Kano, M. (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29, 729-738.
85. Gerdeman, G. L., Ronesi, J., and Lovinger, D. M. (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5, 446-451.
86. Lucas, D. R. and Newhouse, J. P. (1957) The toxic activity of sodium-L-glutamate on the inner layers of the retina. Arch. Opthalmol. 58, 192-201.
87. Olney, J. W. (1971) Glutamate-induced neuronal necrosis in the infant mouse hypothalamus. An electron microscopic study. J. Neuropathol. Exp. Neurol. 30, 75-90.
88. Lee, J. M., Zipfel, G. J., and Choi, D. W. (1999) The changing landscape of ischaemic brain injury mechanisms. Nature 399, A7-14.
89. Kermer, P., Klocker, N., and Bahr, M. (1999) Neuronal death after brain injury. Models, mechanisms, and therapeutic strategies in vivo. Cell Tissue Res. 298, 383-395.
90. Ishimaru, M. J., Ikonomidou, C., Tenkova, T. I., et al. (1999) Distinguishing excitotoxic from apoptotic neurodegeneration in the developing rat brain. J. Comp. Neurol. 408, 461-476.
91. Faden, A. I., Demediuk, P., Panter, S. S., and Vink, R. (1989) The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244, 798-800.
92. Rothman, S. M. and Olney, J. W. (1986) Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19, 105-111.
93. Siesjo, B. K. (1992) Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. J. Neurosurg. 77, 169-184.
94. Doble, A. (1999) The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol. Ther. 81, 163-221.
95. Rossi, D. J., Oshima, T., and Attwell, D. (2000) Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 403, 316-321.
96. Koch, R. A. and Barish, M. E. (1994) Perturbation of intracellular calcium and hydrogen ion regulation in cultured mouse hippocampal neurons by reduction of the sodium ion concentration gradient. J. Neurosci. 14, 2585-2593.
97. Rothman, S. M. (1985) The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J. Neurosci. 5, 1483-1489.
98. Choi, D. W. (1995) Calcium: Still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 18, 58-60.
99. Stout, A. K., Raphael, H. M., Kanterewicz, B. I., Klann, E., and Reynolds, I. J. (1998) Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat. Neurosci. 1, 366-373.
100. Pang, Z. and Geddes, J. W. (1997) Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: Acute excitotoxic necrosis and delayed apoptosis. J. Neurosci. 17, 3064-3073.
101. Dijkhuizen, R. M., van Lookeren Campagne, M., Niendorf, T., et al. (1996) Status of the neonatal rat brain after NMDA-induced excitotoxic injury as measured by MRI, MRS and metabolic imaging. NMR Biomed. 9, 84-92.
102. 2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J. Neurochem. 59, 1211-1220.
103. Velasco, I., Tapia, R., and Massieu, L. (1996) Inhibition of glutamate uptake induces progressive accumulation of extracellular glutamate and neuronal damage in rat cortical cultures. J. Neurosci. Res. 44, 551-561.
104. Pellegrini-Giampietro, D. E., Cherici, G., Alesiani, M., Carla, V., and Moroni, F. (1990) Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J. Neurosci. 10, 1035-1041.
105. Goldberg, M. P. and Choi, D. W. (1993) Combined oxygen and glucose deprivation in cortical cell culture: Calcium-dependent and calcium-independent mechanisms of neuronal injury. J. Neurosci. 13, 3510-3524.
106. Abdel-Hamid, K. M. and Tymianski, M. (1997) Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins. J. Neurosci. 17, 3538-3553.
107. Choi, D. W., Maulucci-Gedde, M., and Kriegstein, A. R. (1987) Glutamate neurotoxicity in cortical cell culture. J. Neurosci. 7, 357-368.
108. Abood, M. E., Rizvi, G., Sallapudi, N., and McAllister, S. D. (2001) Activation of the CB(1) cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309, 197-201.
109. Skaper, S. D., Buriani, A., Dal Toso, R., Petrelli, L., Romanello, S., Facci, L., and Leon, A. (1996) The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA 93, 3984-3989.
110. Shen, M. and Thayer, S. A. (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54, 459-462.
111. Hampson, A. J., Grimaldi, M., Axelrod, J., and Wink, D. (1998) Cannabidiol and (-) Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95, 8268-8273.
112. Sinor, A. D., Irvin, S. M., and Greenberg, D. A. (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278, 157-160.
113. Hampson, A. J. and Grimaldi, M. (2001) Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur. J. Neurosci. 13, 1529-1536.
114. Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K., and Greenberg, D. A. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987-2995.
115. Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., and Behl, C. (2002) Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. J. Neurochem. 80, 448-456.
116. Gallily, R., Breuer, A., and Mechoulam, R. (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur. J. Pharmacol. 406, R5-7.
117. Smith, M. L., Bendek, G., Dahlgren, N., Rosen, I., Wieloch, T., and Siesjo, B. K. (1984) Models for studying long-term recovery following forebrain ischemia in the rat. 2. A 2-vessel occlusion model. Acta. Neurol. Scand. 69, 385-401.
118. Pulsinelli, W. A. and Brierley, J. B. (1979) A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 10, 267-272.
119. Kameyama, M., Suzuki, J., Shirane, R., and Ogawa, A. (1985) A new model of bilateral hemispheric ischemia in the rat - Three vessel occlusion model. Stroke 16, 489-493.
120. Ito, U., Spatz, M., Walker, J. T., Jr., and Klatzo, I. (1975) Experimental cerebral ischemia in mongolian gerbils. I. Light microscopic observations. Acta. Neuropathol. (Berl.). 32, 209-223.
121. Garcia, J. H., Wagner, S., Liu, K. F., and Hu, X. J. (1995) Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 26, 627-635.
122. Dixon, C. E., Lyeth, B. G., Povlishock, J. T., et al. (1987) A fluid percussion model of experimental brain injury in the rat. J. Neurosurg. 67, 110-119.
123. Shapira, Y., Shohami, E., Sidi, A., Soffer, D., Freeman, S., and Cotev, S. (1988) Experimental closed head injury in rats: Mechanical, pathophysiologic, and neurologic properties. Cri. Car. Med. 16, 258-265.
124. Lighthall, J. W. (1988) Controlled cortical impact: A new experimental brain injury model. J. Neurotrauma 5, 1-15.
125. Louw, D. F., Yang, F. W., and Sutherland, G. R. (2000) The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 857, 183-187.
126. Muthian, S. and Hillard, C. J. (2000) CB1 receptor antagonists are neuroprotective in focal cerebral ischemia-reperfusion injury, in Symposium on the Cannabinoids 107 (ICRS, Burlington, Vermont, 2000).
127. Braida, D., Pozzi, M., and Sala, M. (2000) CP55,940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci. Lett. 296, 69-72.
128. Wagner, J. A., Hu, K., Bauersachs, J., et al. (2001) Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. 38, 2048-2054.
129. van der Stelt, M., Veldhuis, W. B., Bar, P. R., Veldink, G. A., Vliegenthart, J. F., and Nicolay, K. (2001) Neuroprotection by Delta 9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21, 6475-6479.
130. Mechoulam, R., Panikashvili, D., and Shohami, E. (2002) Cannabinoids and brain injury: Therapeutic implications. Trends Mol. Med. 8, 58-61.
131. Schmid, H. H., Schmid, P. C., and Natarajan, V. (1990) N-acylated glycerophospholipids and their derivatives. Prog. Lipid. Res. 29, 1-43.
132. Kempe, K., Hsu, F. F., Bohrer, A., and Turk, J. (1996) Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. J. Biol. Chem. 271, 17,287-17,295.
133. Hansen, H. S., Moesgaard, B., Hansen, H. H., Schousboe, A., and Petersen, G. (1999) Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity. Lipids 34, S327-S330.
134. Hansen, H. H., Hansen, S. H., Schousboe, A., and Hansen, H. S. (2000) Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons. J. Neurochem. 75, 861-871.
135. Hansen, H. H., Ikonomidou, C., Bittigau, P., Hansen, S. H., and Hansen, H. S. (2001) Accumulation of the anandamide precursor ad other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem. 76, 39-46.
136. Hansen, H. S., Lauritzen, L., Strand, A. M., Vinggaard, A. M., Frandsen, A., and Schousboe, A. (1997) Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. J. Neurochem. 69, 753-761.
137. Hansen, H. H., Schmid, P. C., Bittigau, P., (2001) et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78, 1415-1427.
138. Panikashvili, D., Simeonidou, C., Ben-Shabat, S., Hanus, L., Breuer, A., Mechoulam, R., and Shohami, E. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531.
139. Sugiura, T., Yoshinaga, N., Kondo, S., Waku, K., and Ishima, Y. (2000) Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem. Biophys. Res. Commun. 271, 654-658.
140. Jin, K. L., Mao, X. O., Goldsmith, P. C., and Greenberg, D. A. (2000) CB1 cannabinoid receptor induction in experimental stroke. Ann. Neurol. 48, 257-261.
141. van der Stelt, M., Veldhuis, W. B., van Haaften, G. W., et al. (2001) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21, 8765-8771.
142. Andersson, M., Jacobsson, S. O., Jonsson, K. O., Tiger, G., and Fowler, C. J. (2000) Neurotoxicity of glutamate in chick telencephalon neurons: Reduction of toxicity by preincubation with carbachol, but not by the endogenous fatty acid amides anandamide and palmitoylethanolamide. Arch. Toxicol. 74, 161-164.
143. Chan, G. C., Hinds, T. R., Impey, S., and Storm, D. R. (1998) Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J. Neurosci. 18, 5322-5332.
144. Stella, N, and Piomelli, D. (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425, 189-196.
145. Shen, M. and Thayer, S. A. (1998) The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 783, 77-84.
146. Denovan-Wright, E. M. and Robertson, H. A. (2000) Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705-713.
147. Lastres-Becker, I., Fezza, F., Cebeira, M., et al. (2001) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 12, 2125-2129.
148. Zimmer, A., Zimmer, A. M., Hohmann, A. G., Herkenham, M., and Bonner, T. I. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 5780-5785.
149. Lambert, D. M., Vandevoorde, S., Diependaele, G., Govaerts, S. J., and Robert, A. R. (2001) Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia 42, 321-327.
150. Johnson, D. E., Heald, S. L., Dally, R. D., and Janis, R. A. (1993) Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Prostaglandins Leukot. Essent. Fatty Acids 48, 429-437.
151. Sasamura, T. and Kuraishi, Y. (1999) Peripheral and central actions of capsaicin and VR1 receptor. Jpn. J. Pharmacol. 80, 275-280.
152. Grant, E. R., Dubin, A. E., Zhang, S. P., Zivin, R. A., and Zhong, Z. (2002) Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: A method to resolve ionic dependence of VR1-mediated cell death. J. Pharmacol. Exp. Ther. 300, 9-17.
153. Premkumar, L. S. and Ahern, G. P. (2000) Induction of vanilloid receptor channel activity by protein kinase C. Nature 408, 985-990.
154. De Petrocellis, L., Harrison, S., Bisogno, T., et al. (2001) The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J. Neurochem. 77, 1660-1663.
155. Mattson, M. P., Culmsee, C., and Yu, Z. F. (2000) Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res. 301, 173-187.
156. Mattson, M. P. (2000) Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell. Biol. 1, 120-129.
157. Schwarz, H., Blanco, F. J., and Lotz, M. (1994) Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol, 55, 107-115.
158. Sarker, K. P., Obara, S., Nakata, M., Kitajima, L., and Maruyama, I. (2000) Anandamide induces apoptosis of PC-12 cells: Involvement of superoxide and caspase-3, FEBS Lett. 472, 39-44.
159. Galve-Roperh, I., Sanchez, C., Cortes, M. L., del Pulgar, T. G., Izquierdo, M., and Guzman, M. (2000) Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6, 313-319.
160. Guzman, M., Sanchez, C., and Galve-Roperh, I. (2001) Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78, 613-625.
161. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P., and Guzman, M. (1998) Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436, 6-10.
162. Ruiz, L., Miguel, A., and Diaz-Laviada, I. (1999) Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett. 458, 400-404.
163. De Petrocellis, L., Melck, D., Palmisano, A., Bisogno, T., Laezza, C., Bifulco, M., and Di Marzo, V. (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA 95, 8375-8380.
164. Melck, D., Rueda, D., Galve-Roperh, I., De Petrocellis, L., Guzman, M., and Di Marzo, V. (1999) Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 463, 235-240.
165. Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M., and Di Marzo, V. (2000) Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, 118-126.
166. Bifulco, M., Laezza, C., Portella, G., Vitale, M., Orlando, P., De Petrocellis, L., and Di Marzo, V. (2001) Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB. J. 15, 2745-2747.
167. Guzman, M., Galve-Roperh, I., and Sanchez, C. (2001) Ceramide: A new second messenger of cannabinoid action. Trends Pharmacol. Sci. 22, 19-22.
168. Sanchez, C., de Ceballos, M. L., del Pulgar, T. G., et al. (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61, 5784-5789.
169. Sanchez, C., Rueda, D., Segui, B., Galve-Roperh, I., Levade, T., and Guzman, M. (2001) The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol. Pharmacol. 59, 955-959.
170. Rueda, D., Galve-Roperh, I., Haro, A., and Guzman, M. (2000) The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. 58, 814-820.
171. Gomez del Pulgar, T., Velasco, G., and Guzman, M. (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. 347, 369-373.
172. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., and Finazzi-Agro, A. (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275, 31,938-31,945.
173. Wahl, G. M. and Carr, A. M. (2001) The evolution of diverse biological responses to DNA damage: Insights from yeast and p53. Nat. Cell. Biol. 3, E277-E286.
174. Jacobsson, S. O., Wallin, T., and Fowler, C. J. (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299, 951-959.
175. Klein, M., Calderon, S., and Hayes, B. (1999) Abuse liability assessment of neuroprotectants. Ann. NY Acad. Sci. 890, 515-525.
176. Shohami, E. and Mechoulam, R. (2000) A non-psychotropic cannabinoid with neuroprotective properties. Drug Dev. Res. 50, 211-215.